Preclinical biosafety evaluation of cell-based therapies: emerging global paradigms (Q26829230)

B. T. Assaf

series ordinal

2

1 reference

T. A. Bertram

series ordinal

3

1 reference

M. Rao

series ordinal

4

1 reference

language of work or name

1 reference

January 2015

1 reference

published in

Toxicologic Pathology

1 reference

volume

43

1 reference

issue

1

1 reference

page(s)

115-25

1 reference

Induction of pluripotent stem cells from adult human fibroblasts by defined factors

cites work

1 reference

https://api.crossref.org/works/10.1177/0192623314559104

Site-directed mutagenesis by gene targeting in mouse embryo-derived stem cells

20 April 2017

1 reference

https://api.crossref.org/works/10.1177%2F0192623314559104

US Food and Drug Administration international collaborations for cellular therapy product regulation

20 April 2017

1 reference

https://api.crossref.org/works/10.1177%2F0192623314559104

Platform technologies for tubular organ regeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623314559104

Developmental engineering the kidney: leveraging principles of morphogenesis for renal regeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623314559104

Mesenchymal stem cells in hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623314559104

Altering the genome by homologous recombination

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623314559104

The MSC: An Injury Drugstore

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623314559104

Regulatory considerations for the development of autologous induced pluripotent stem cell therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623314559104

Mesenchymal stem cells in the umbilical cord: phenotypic characterization, secretome and applications in central nervous system regenerative medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623314559104

Athletes' use of unproven stem cell therapies: adding to inappropriate media hype?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623314559104

Cell-Based Therapy for Neural Disorders — Anticipating Challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623314559104

China's stem-cell rules go unheeded

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623314559104

Human induced pluripotent stem cells: a review of the US patent landscape

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623314559104

Potency evaluation of tissue engineered and regenerative medicine products

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623314559104

Cell and tissue therapy regulation: worldwide status and harmonization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623314559104

Stem cell-based cell therapy in neurological diseases: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623314559104

Future research and therapeutic applications of human stem cells: general, regulatory, and bioethical aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623314559104

A review of the methods for human iPSC derivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623314559104

Mesenchymal stem cells and tissue engineering

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623314559104

Efficient reprogramming of human cord blood CD34+ cells into induced pluripotent stem cells with OCT4 and SOX2 alone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623314559104

Public private partnerships: a marriage of necessity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623314559104

Concise review: Cord blood banking, transplantation and induced pluripotent stem cell: success and opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623314559104

Funding Translational Work in Cell-Based Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623314559104

Adoptive cell transfer: a clinical path to effective cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623314559104

European regulation tackles tissue engineering

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623314559104

Mesenchymal stem cells, cancer challenges and new directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623314559104

Stem cells. U.S. regulation of stem cells as medical products

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623314559104

Induction of pluripotent stem cells from fibroblast cultures

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623314559104

Therapeutic gene products delivery by neuron stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623314559104

Human cord blood applications in cell therapy: looking back and look ahead

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623314559104

The expanding world of tissue engineering: the building blocks and new applications of tissue engineered constructs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623314559104

Hemacord approval may foreshadow regulatory creep for HSC therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623314559104

7 January 2021

Peripheral blood stem cell donation: an analysis from the International Bone Marrow Transplant Registry (IBMTR) and European Group for Blood and Marrow Transplant (EBMT) databases

1 reference

https://api.crossref.org/works/10.1177%2F0192623314559104

7 January 2021

Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report

1 reference

https://api.crossref.org/works/10.1177%2F0192623314559104

7 January 2021

Cell Therapy Using Induced Pluripotent Stem Cells or Somatic Stem Cells: This is the Question

1 reference

https://api.crossref.org/works/10.1177%2F0192623314559104

7 January 2021

Identifiers

DOI

10.1177/0192623314559104

1 reference

PubMed publication ID

25476796

1 reference